Girish Bhatia

A prospective, randomized, double‐blind, multicentre, parallel‐group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia;<scp>ZRC</scp>‐3197) and adalimumab (Humira) in patients with rheumatoid arthritis

Rajendrakumar H. Jani, Rajiv Gupta, Girish Bhatia et al. · International Journal of Rheumatic Diseases · 2015 · 62 citations · Full text

A Comparative Study to Assess the Efficacy, Safety, and Immunogenicity of YLB113 and the Etanercept Reference Product for the Treatment of Patients with Rheumatoid Arthritis

Hisashi Yamanaka, Naoyuki Kamatani, Yoshiya Tanaka et al. · Rheumatology and Therapy · 2019 · 20 citations · Full text

OP0012 A Phase 3, Randomized, Double-Blind, Active Comparator Study of the Efficacy and Safety of Bow015, A Biosimilar Infliximab, in Patients with Active Rheumatoid Arthritis on Stable Methotrexate Doses

Jonathan Kay, Arvind Chopra, S Chandrashekara et al. · Annals of the Rheumatic Diseases · 2014 · 16 citations

A Randomized, Double-Blind, Parallel-Group Phase III Trial Investigating the Glycemic Efficacy and Safety Profile of Fixed-Dose Combination Dapagliflozin and Linagliptin Over Linagliptin Monotherapy in Patients with Inadequately Controlled Type 2 Diabetes with Metformin

Aditi Jain, Abhay Vispute, Amol Dange et al. · Diabetes Therapy · 2023 · 12 citations · Full text